We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EMA’s Committee for Medicinal Products for Human Use recommended seven medicines at its Dec. 10-13 meeting for approval by the European Commission. Read More
The agency based its approval on a Phase 3 trial that showed the regimen led to patients living significantly longer than with Avastin and chemotherapy alone. Read More
The European Commission based its approval on a Phase 3 clinical trial showing vision improvement as early as 30 days following treatment. Vision improved for 90 percent of trial subjects. Read More